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Abstract
Malignancy is one of the most common causes of hypercalcemia, particularly in cancer associated with bone metastases. Hypercalcemia occurs in up to 20% to 30%
of cancer patients at some time during the course of their disease. Clinical manifestations of hypercalcemia vary in calcium level in blood. Signs and symptoms of
hypercalcemia occur when the serum calcium level rises above those ranges. Fluids are first-line treatment with hypercalcemia followed by bisphosphanates if the
calcium is high and the patient is experiencing symptoms. Various other medications are used as second-line agents in hypercalcemia of malignancy.

Introduction
Hypercalcemia is defined as a condition in which the serum
calcium level is above normal level (> 10.5 mg/dL or ionized Ca
level > 5.6 mg/dL). The consequences of abnormal serum calcium
level can range from asymptomatic to life-threatening. In addition,
excessively high serum calcium level causes clinical manifestations
that affect the neuromuscular, gastrointestinal, renal, skeletal, and
cardiovascular systems [1,2]. Malignancy is one of the most common
causes of hypercalcemia, particularly in cancer associated with bone
metastases. Since some tumor cells can resorb or destroy bone directly,
hypercalcemia develops more rapidly and more aggressively than other
causes of hypercalcemia, along with classic symptoms of dehydration,
anorexia, nausea/vomiting, constipation, and polyuria. In multiple
myeloma, for example, malignant myeloma cells secrete a cytokine
(IL-6 receptor) that activate osteoclasts in vicinity of the myeloma cells
leading to bone resorption. Hypercalcemia associated with malignancy
is a common complication of some types of cancer, including
squamous cell carcinomas, multiple myeloma, T-cell lymphoma, and
breast carcinoma.

Epidemiology and etiology
The most common causes of hypercalcemia in the United States are
primary hyperthyroidism and malignancy. Hypercalcemia occurs in
up to 20% to 30% of cancer patients at some time during the course of
their disease, and predominantly encountered in hospitalization case,
whereas primary hyperthyroidism accounts for the majority of cases in
outpatient case [1,2]

Symptom overview
Clinical manifestations of hypercalcemia vary in calcium level in

Pathophysiology
There are our major types of hypercalcemia associated with cancer:
humoral hyperclacemia of malignancy, local osteolytic hypercalcemia,
calcitriol-secreting lymphoma, and ectopic hyperparathyroidism [1].
Humoral hypercalcemia of malignancy (HHM) is the most common
mechanism of hypercalcemia in the cancer patients. Many cancer
cells secrete parathyroid hormone-related protein (PTHrP), which
binds to the parathyroid receptors in bones and renal tissues, resulting
in increased bone resorption and renal tubular reabsorption. This
mechanism can be associated with any types of cancer, but it is most
commonly associated with squamous-cell cancers (head/neck lung,
esophagus, and skin), renal cancer, ovarian or endometrial cancer,
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breast cancer, and human T-cell leukemia virus-I associated with
lymphoma [3]. The diagnosis of humoral hypercalcemia of malignancy
can be confirmed by an elevated serum PTH-related protein. However,
HHM is distinguished from primary parathyroidism by low level of
parathyroid hormone and 1,25-dihydroxyvitamin D (calcitriol). Local
osteolytic Hypercalcemia (LOH), account for about 20% of the cases
of hypercalcemia of malignancy, is associated with extensive bone
involvement by metastatic disease leading to high bone resorption and
osteolytic lesions [3]. Tumor cells found in the bone marrow secrete
stimulatory factors (IL-1 and 6, prostaglandin E2, TNF, PTHrP,
and macrophage colony-stimulating factor) enhancing osteoclast
activity [3]. Hypercalcemia patients associated with Local osteolytic
Hypercalcemia are differentiated from Primary hyperthyroidism and
Humoral hypercalcemia of malignancy by normal or slightly elevated
PO4 levels, normal level of immunoreactive PTHrP, and presence
of bone metastases or bone marrow infiltration [3]. This mechanism
is typically associated with breast cancer, multiple myeloma, and
lymphoma [1]. The other causes of hypercalcemia of malignancy are
calcitriol-mediated hypercalcemia and ectopic PTH secretion. Those
types are relatively rare causes of hypercalcemia, account for less than
1% of cases. All histologic subtypes of lymphoma may produce the
active form of vitamin D (calcitriol) that leads to increase absorption
of calcium in intestine [3]. Ectopic hyperparathyroidism is the most
rare cause of hypercalcemia in malignancy. It causes hypercalcemia as
a result of the ectopic production and secretion of intact parathyroid
hormone by neuroendocrine tumor [3].
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blood. Normal range of serum calcium level is 8.5 to 10.5 mg/dL and
normal range of ionized calcium level is 4 to 5.6 mg/dL. The severity of
hypercalcemia is classified into three categories based on the level of
total serum calcium (Figure 1).
Patients with mild to moderate hypercalcemia, which is total serum
calcium between 10.5 and 12 mg/dL or of ionized calcium between
5.6 to 8 mg/dL, can be asymptomatic [2]. The presenting signs and
symptoms of hypercalcemia occur when the serum calcium level rises
above those ranges. Patients with a chronic calcium level of 12 to 14
mg/dL may tolerate those levels well, whereas sudden development of
hypercalcemia in this range or higher may lead to dramatic changes
in a patient’s mental status. The mnemonic “stones, bones, abdominal
moans, and psychic groans” describes the constellation of symptoms
and signs of hypercalcemia [2]. The clinical manifestations of
hypercalcemia include: Central nervous system effects include lethargy,
impaired concentration, fatigue, and muscle weakness; Renal effects
include dehydration, polyuria, nocturia, nephrolithiasis resulting from
hypercalciuria, nephrogenic diabetic insipidus, and nephrocalcinosis;
Gastrointestinal effects include nausea, vomiting, anorexia,
weight loss, constipation, abdominal pain, pancreatitis, and PUD;
Cardiovascular effects include hypertension, shortened QT interval on
electrocardiogram, cardiac arrhythmias, vascular calcification. Other
symptoms include bone pain, arthritis, and osteoporosis. [2].

Treatment options (Dose, frequency, titration
parameters, time to effect/symptom resolution,
expected effects, special or target populations for
specific therapies, side effects and their management)
The optimal therapy for hypercalcemia of malignancy is dependent
on the severity of hypercalcemia and underlying causes. Hypercalcemia
associated with malignancy would be resolved with definitive antitumor
therapy of the underlying cancer with chemotherapy [3]. If it is not
resolved with proper anticancer therapy, anti-hypercalcemic therapy
focusing on targeting the pathophysiologic mechanisms should be
considered. It is essential that withholding anti-hypercalcemic therapy
may result in life-threatening emergency such as coma and death.
Asymptomatic patients with mild hypercalcemia (serum Ca level
of 10.5 to 12 mg/dL) generally do not require immediate treatment.
The general supportive cares for hypercalcemia includes the removal

calcium intake from any sources (IV, PO Ca supplements), an increase
in oral free water intake, discontinuation of medications causing
hypercalcemia (thiazide diuretics, lithium, vitamin D, carbonate
therapy), an increase in the weight-bearing ambulation/activities, and
discontinuation of sedative drugs analgesics [2]. Symptomatic patient
with serum Ca levels greater than 12 mg/dL or patients with serum Ca
levels greater than 14 mg/dL should be immediately and aggressively
treated with anti-hypercalcemic therapy: hydration with saline
rehydration followed by loop diuretics, calcitonin, bisphosphonates,
and denosumab. For the majority of cancer patients with hypercalcemia
have Humoral Hypercalcemia of malignancy (HHM) and Local
Osteolytic Hypercalcemia (LOH), intravenous bisphosphonates or
subcutaneous/intramuscular calcitonin or subcutaneous denosumab
can be used to inhibit osteoclast-mediated bone resorption. Calcitriolmediated hypercalcemia is treated with intravenous glucocorticoid
therapy along with limitation of calcium intake to inhibit vitamin D
conversion to calcitriol. All pharmacologic therapy for hypercalcemia
of malignancy is summarized in Table 1.

Hydration with normal saline followed by low-dose
furosemide
Most patients with hypercalcemia associated with malignancy are
dehydrated as a result of renal dysfunction induced by hypercalcemia
and by decreased oral fluid intake resulting from nausea and vomiting.
Therefore, the cornerstone of initial treatment of hypercalcemia is
volume expansion with intravenous normal saline to increase the
glomerular filtration rate and renal calcium excretion. Rehydration can
be accomplished by IV normal saline at rate of 200 to 500 ml/hr or
2 to 4 liter per day depending on renal function, the baseline status
of dehydration, and the severity of hypercalcemia. Hydration with
normal saline should be continued until patients are fully resuscitated,
serum calcium level is corrected within the normal range, and the urine
output is maintained at 200 ml/hr [1,2]. The hydration state is assessed
by measuring fluid intake and output or by central venous pressure
monitoring. However, the aggressive hydration can exacerbate heart
failure in elderly patients, the use of hydration is limited in patients
with congestive heart failure. Once intravascular volume has been
restored, low-dose of furosemide (20-40mg IV) every 1 to 4 hours can
be used to further lower the serum calcium level and or prevent the
development of volume overload from normal saline administration;
it block calcium reabsorption in the loop of Henle and increase urine
output leading possible increased saline administration, which induces
further calcium renal excretion [1].

Bisphosphonates; first-line medications

Figure 1. Severity of hypercalcemia by serum total/ionized calcium level [2].
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Bisphosphonate therapy should be initiated as soon as
hypercalcemia is discovered, because it takes two to four days to appear
the calcium level lowering effect. The maximum effect generally occurs
within four to seven day after initiation of bisphosphonates. About
60 to 90 percent of patients achieve their normal calcium level within
four to seven days, and response last for one to three weeks [1]. Two
bisphosphonate agents, Pamidronate (Aredia) and Zoledronic acid
(Zometa), are approved by the U.S Food and Drug Administration
for the treatment of hypercalcemia of malignancy. Bisphosphonates
inhibit bone resorption and decrease bone mineralization by disrupting
osteoclast activity. Most commonly reported adverse reactions are renal
toxicity, flu-like symptoms, injection site reactions, hypocalcemia,
hypophosphatemia, fatigue, muscle weakness, and constipation of
diarrhea. Co-administration of oral calcium supplement of 500 mg and
multiple vitamins containing 400 IU of vitamin D are recommended to
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Table 1. Pharmacologic options for Hypercalcemia associated with cancer.
Intervention

MOA

Dose

Adverse Effects

Re-Hydration with NS Followed by Loop diuretics
IV Normal saline

Enhance GFR and renal excretion of Ca2+ 200-500 ml/hr or 2-4 liter/day for 1 to 3 days depending on Volume overload; may exacerbate heart failure
the cardiovascular and renal status of patient

Furosemide

Inhibit Ca2+ resorption in the renal tube

20-40 mg IV; AFTER REHYDATION has been achieved

Hypokalemia, renal failure, abnormalities of
cardiac conduction

First-line medications: Intravenous Bisphosphonate
Pamidronate

Inhibit osteoclast activity; decrease bone
resorption

Zoledronic acid

60-90 mg IV over 2 hr in a solution of 50-200 ml of NS or
D5W
4 mg IV over 15min in a solution of 50 ml NS or D5W

Nephrotoxicity, flu-like symptoms with fever,
chills, headache

Second-line medications
Glucocorticoids

Inhibit vitamin D conversion to calcitriol Oral prednisone 20-40 mg/day for 10 days, IV
hydrocortisone 200 mg daily for 3 days or equivalents

Immune suppression, myopathy, ↑ glucose in
blood, weight gain, ↑ blood pressure

Calcitonin [8]

4-8 IU/kg SQ or IM every 12 hour

May rebound ↑ Ca2+ after 24 hours; cause
vomiting, cramps, flushing

Inhibit bone resorption

Mithramycin

Inhibit osteoclast activity

25 mcg/kg over 4 to 6 hours in NS or D5w solution

Bone marrow suppression, nephron/hepatic toxicity

Gallium nitrate [10]

Inhibit osteoclast activity

IV continuously infusion at 100-200 mg/m2 over 24 hours
for five days

Bone marrow suppression, nephrotoxicity

Table 2. First-line medication for hypercalcemia associated with cancer.

Pamidronate
(Aredia) [6,11]

Dose/Administration

Onset of action

Renal dose adjustment

- Route: Intravenous
- Available in 30 mg, 60 mg, or
90 mg vials for IV administration;
reconstituted with 10 ml of sterile water
or D5W

- initial Ca lowering
effect: 2-4 days
- maximum effects:
about 4 to 7 days
after initiation of
therapy

- severe renal impairment (SCr
> 3mg/ml or CrCr < 30ml/
minutes): reduced initial dose
should be considered.

- Moderate hypercalcemia: 60 to 90 mg
as single dose IV infusion over 4 hours
once every 3 to 4 weeks
- Severe hypercalcemia: 90 mg as single
dose IV infusion over 24 hour

Monitoring parameters

SCr, electrolytes (Ca, PO4,
Mg, K), CBC, hypocalcemia
symptoms for at least 2
weeks after therapy, dental
exam prior to therapy,
-Increase of SCr ≥ 0.5 mg/dL all cancer patients (prein patients with normal baseline existing anemia, leukopenia,
(SCr < 1.4 mg/dL)
thromobocytopenia) should
be monitored during the first
- Increase of SCr ≥ 1 mg/dL in 2 weeks of treatment; urine
patients with abnormal baseline albumin every 3 to 6 months
(SCr ≥ 1.4 mg/dL)
in multiple myeloma patients.

- Retreatment: Recommended that
a minimum of 7 days elapse before
retreatment to allow for full response to
the initial dose.
Zoledronic acid
(Zometa) [7,12]

Pregnancy D:
there are no adequate and wellcontrolled studies in pregnancy.
However, adverse events were
observed in animal reproduction
studies. It is not known if
pamidronate cross the placenta, but
fetal exposure is expected.
Breast-feeding:
Not recommend

- Route: Intravenous
- Similar to
- Available in 4 mg/5ml and 5mg/100ml pamidronate.
vials for IV administration

- Severe renal impairment (SCr Same as Pamidronate
> 4.5 mg/dL): evaluate risk Vs.
benefit

Contraindication: hypersensitivity
to Zoledronic acid or other
bisphosphonates.

- Hypercalcemia of malignancy
(corrected Ca ≥ 12 mg/dL): 4 mg IV
given as a single dose over 15 minutes.

- CrCL > 60 ml/min: 4 mg; no
dosage adjustment is required.

Pregnancy D:
: there are no adequate and wellcontrolled studies in pregnancy.
Theoretically, there may be a risk
of fetal harm when pregnancy
follows the completion of therapy

- CrCL 50-60: reduced dose
to 3.5 mg

- Retreatment: wait at least 7 days
before re-treatment; 4 mg as retreatment

- CrCL 40-49: reduced dose
to 3.3 mg

Breast-feeding:
Not recommend

- CrCL 30-39: reduced dose
to 3 mg
- CrCL < 30: not recommended
Denosumab
(Xgeva) [9]

Note
Contraindication: hypersensitivity
to pamidronate or other
bisphosphonates.

- Subqutaneous
- Available in 120 mg/1.7 mL (70 mg/
mL) solution in a single-use vial
- Treatment of hyperkalemia of
malignancy: 120 mg subcutaneous
every 4 week; give an additional 120
mg on days 8 and 15 during the first
month.

- About 85% patients No hepatic/Renal dose
adjustment
within 3 days;
maximal reductions
observed within 1
months

SCr, serum electrolytes
(Ca, PO4, Mg), s/sx of
hypocalcemia, infection,
injection site reactions, dental
exam

Limitation:
Denosumab is not indicated for
the prevention of skeletal-related
events in patients with multiple
myeloma

- Time to initial
response: median
time 9 days

Contraindication:
Hypersensitivity to Denosumab;
Pre-existing Hypocalcemia

- Time to complete
response: median
time 23 days

Pregnancy D:
Adverse events were observed in
animal reproduction studies.
Breast-feeding:
Not recommend
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prevent hypercalcemia [4-7].

Denosumab (Xgeva); Human monoclonal antibody;
First-line medication
Denosumab, a full human IgG2 monoclonal antibody against
RANKL, can be used for the management of hypercalcemia of
malignancy in patients with persistent hypercalcemia despite
bisphosphonates. Denosumab binds to RANKL (soluble protein
essential for the formation, function, and survival of osteoclast), and
inhibit osteoclast activity resulting in decreased skeletal-related events
and tumor-induced bone destruction [8,9]. Unlike bisphosphonates,
denosumab is not cleared by kidney, and there is no restriction of use
in patients with chronic renal impairment whom bisphosphonates
used with caution or contraindicated [4]. In a clinical trial, 33 patients
with hypercalcemia of malignancy with persistently elevated serum
calcium levels after treatment with zoledronic acid were treated with
denosumab 120 mg subcutaneously weekly for 4 weeks and monthly
thereafter [5]. In case reports of hypercalcemia patients with multiple
myeloma and severe renal impairment, denosumab decreased serum
calcium level within 2 to 4 days, and in one case was associated with
improvement in renal function [9] (Table 2).

Second-line medications: Glucocorticoid, mithramycin,
calcitonin, gallium nitrate
Glucocorticoids can be used in treatment option for hypercalcemia
patients with excessive administration of vitamin D or the endogenous
overproduction of calcitriol secondary to lymphoma [1]. In those
condition, glucocorticoids such as oral prednisone 20-40 mg/day for
10 days, IV hydrocortisone 200 mg daily for 3 days or equivalents [1,3].
Calcitonin can be used as alternative to saline hydration therapy
for patients with severe chronic heart failure or moderate to severe
renal dysfunction. The initiation of subcutaneous calcitonin may result
in a more rapid reduction in serum calcium levels than other agents
(maximal response occurs within 12 to 24 hours), but the effect and
extent of serum calcium level reduction are often erratic [1].
Mitramycin (plicamycin), a potent cytotoxic antibiotic, reduce
serum calcium level by inhibiting osteoclast-mediated bone resorption.
Mithramycin is administered via IV infusion at 25 mcg/kg over 4 to 6
hours in normal saline or D5w solution [1]. This therapy can be repeated
daily for 3 to 4 days, and the serum calcium lowering effect begin to fall
within 12 hours of initiation. However, mithramycin is not commonly
recommended in hypercalcemia associated with malignancy due to
dose-related adverse effects including nausea, vomiting, stomatitis,
thrombocytopenia, and renal and hepatotoxicity.
Gallium nitrate is approved for treatment in hypercalcemia of
malignancy. This agent decrease serum calcium level by inhibiting
osteoclast activity. It is given via IV continuously infusion at 100-200
mg/m2 over 24 hours for five days [1]. The common adverse events
are renal dysfunction, hypocalcemia, hypophosphatemia, decreased
serum bicarbonates, and hypotension. Since Administration of
Gallium nitrate required continuous IV infusion over 24 hours, it is
not commonly used [10-12].
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Summery
Hypercalcemia of malignancy is a one of the most common
complication of advanced breast cancer, squamous cell cancers, and
multiple myeloma. Those types of cancer are highly associated with
bone metastases or skeletal involvement. Therefore, hypercalcemia
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develops more quickly than other causes such as parathyroid hormonerelated, medications-related, vitamin D-related, and genetic disorders
[2]. The development of this cancer-associated with complication is
associated with a poor prognosis, and severe/acute hypercalcemia leads
to severe mental impairment, renal failure, and life-threatening medical
emergency. Clinical manifestations of hypercalcemia vary in the level
of calcium in the blood, and the severity of hypercalcemia is classified
into three categories based on the serum calcium level: mild, moderate,
hypercalcemic crisis [2]. There are four mechanisms of hypercalcemia
in the cancer patient: humoral hyperclacemia of malignancy, local
osteolytic hypercalcemia, calcitriol-secreting lymphoma, and ectopic
hyperparathyroidism [1,3]. Humoral hyperclacemia of malignancy
and local osteolytic hypercalcemia are most common causes of
hypercalcemia of malignancy, and the others are relatively rare causes
of hypercalcemia, which account for less than 1% of cases. For the
clinical intervention in the management of hypercalcemia, aggressive
hydration with normal saline and intravenous bisphosphonates
are first-line pharmacological options. Since most patients with
hypercalcemia are dehydrated as a result of renal dysfunction induced
by hypercalcemia or by decreased in oral fluid intake from nausea/
vomiting, hydration with normal saline should be initiated to increase
the glomerular filtration rate and renal calcium excretion. In addition,
volume expansion with normal saline dilutes calcium concentration in
the blood, and inhibits calcium reabsorption in the proximal nephron;
saline act as calciuretic [1]. After rehydration has been achieved,
Loop diuretic, low-dose of furosemide can be used to prevent volume
overload and to induce further renal calcium excretion. Intravenous
bisphosphonates and subcutaneous denosumab can be used for
severe hypercalcemia associated with cancer; those agents inhibit
osteoclast activity and decrease bone resorption. Bisphosphonate
agents, pamidronate and zoledronic acid, are not metabolized and
are exclusively eliminated by renal excretion [6,7]. Therefore, dose
of those agents are should be adjusted by patient’s renal function,
and are contraindicated in patients with severe renal impairment.
Denosumab is also first-line option for hypercalcemia associated with
malignancy, but it is not commonly used as first-line due to high cost;
its generic version is not available in the United States and price is
much expensive than generic version of bisphosphonates. Therefore,
denosumab can be used as alternative to bisphosphonates for patients
with severe renal impairment. There are several agents could be
used as second-line option when bisphosphonates are ineffective
or contraindicated. Glucocorticoid is not commonly used, but it is
effective in hypercalcemia-induced by endogenous overproduction
of calcitriol or excessive ingestion of vitamin D. Calcitonin is safe and
nontoxic, and its serum calcium lowering effect is much faster than
other agents. However, the efficacy of calcitonin is often erratic, and the
duration of calcium lowering effect is relatively short [2]. Mithramycin
is not commonly used in hypercalcemia of malignancy due to its severe
adverse effects. Finally, gallium nitrate is also approved for treatment,
but the need of continuous IV infusion over 24 hours for 5 days limits
its use in hypercalcemia of malignancy [1].
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